163 related articles for article (PubMed ID: 30914025)
1. Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells.
Nkembo AT; Amissah F; Ntantie E; Poku RA; Salako OO; Ikpatt OF; Lamango NS
Curr Cancer Drug Targets; 2019; 19(10):838-851. PubMed ID: 30914025
[TBL] [Abstract][Full Text] [Related]
2. Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer.
Ntantie E; Fletcher J; Amissah F; Salako OO; Nkembo AT; Poku RA; Ikpatt FO; Lamango NS
Oncotarget; 2017 May; 8(19):31726-31744. PubMed ID: 28423648
[TBL] [Abstract][Full Text] [Related]
3. Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.
Tawfeeq N; Lazarte JMS; Jin Y; Gregory MD; Lamango NS
Oncotarget; 2023 Mar; 14():243-257. PubMed ID: 36961909
[TBL] [Abstract][Full Text] [Related]
4. Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling.
Lamango NS; Nkembo AT; Ntantie E; Tawfeeq N
Curr Med Chem; 2021; 28(18):3476-3489. PubMed ID: 33176634
[TBL] [Abstract][Full Text] [Related]
5. Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells.
Poku RA; Salako OO; Amissah F; Nkembo AT; Ntantie E; Lamango NS
Am J Cancer Res; 2017; 7(7):1515-1527. PubMed ID: 28744401
[TBL] [Abstract][Full Text] [Related]
6. Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion.
Lazarte JMS; Lamango NS
Biomedicines; 2024 Feb; 12(3):. PubMed ID: 38540084
[TBL] [Abstract][Full Text] [Related]
7. Disruption of actin filaments and suppression of pancreatic cancer cell viability and migration following treatment with polyisoprenylated cysteinyl amides.
Nkembo AT; Salako O; Poku RA; Amissah F; Ntantie E; Flores-Rozas H; Lamango NS
Am J Cancer Res; 2016; 6(11):2532-2546. PubMed ID: 27904769
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors.
Tawfeeq N; Jin Y; Lamango NS
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830912
[TBL] [Abstract][Full Text] [Related]
9. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Ohm AM; Tan AC; Heasley LE; Reyland ME
Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
[TBL] [Abstract][Full Text] [Related]
10. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
[TBL] [Abstract][Full Text] [Related]
11. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
12. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions.
Zhang Y; Meng X; Tang H; Cheng M; Yang F; Xu W
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):344-353. PubMed ID: 31851852
[TBL] [Abstract][Full Text] [Related]
14. Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.
Aguilar BJ; Nkembo AT; Duverna R; Poku RA; Amissah F; Ablordeppey SY; Lamango NS
Eur J Med Chem; 2014 Jun; 81():323-33. PubMed ID: 24852279
[TBL] [Abstract][Full Text] [Related]
15. The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety.
Nkembo AT; Ntantie E; Salako OO; Amissah F; Poku RA; Latinwo LM; Lamango NS
Oncotarget; 2016 Oct; 7(42):68194-68205. PubMed ID: 27626690
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
17. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
18. Flavopiridol's effects on metastasis in KRAS mutant lung adenocarcinoma cells.
Dogan Turacli I; Demirtas Korkmaz F; Candar T; Ekmekci A
J Cell Biochem; 2019 Apr; 120(4):5628-5635. PubMed ID: 30317654
[TBL] [Abstract][Full Text] [Related]
19. Suppression of reactive oxygen species-mediated ERK and JNK activation sensitizes dihydromyricetin-induced mitochondrial apoptosis in human non-small cell lung cancer.
Kao SJ; Lee WJ; Chang JH; Chow JM; Chung CL; Hung WY; Chien MH
Environ Toxicol; 2017 Apr; 32(4):1426-1438. PubMed ID: 27539140
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
